Effect of HEPA Filtration Air Purifiers on Blood Pressure: A Pragmatic Randomized Crossover Trial
- PMID: 40767818
- DOI: 10.1016/j.jacc.2025.06.037
Effect of HEPA Filtration Air Purifiers on Blood Pressure: A Pragmatic Randomized Crossover Trial
Abstract
Background: Particulate matter (PM) pollution is a leading cause of cardiovascular risk and illness, including elevated blood pressure (BP).
Objectives: The purpose of this study was to test the efficacy of in-home air purifiers to reduce BP for adults living adjacent to highways.
Methods: We conducted a pragmatic randomized crossover trial of the effect of high-efficiency particulate arrestance (HEPA) vs sham filtration on BP. Residences were randomized to start with 1 month of HEPA filtration or 1 month of sham filtration. A 1-month wash out period with no filtration was followed by 1 month of the alternate filtration. Participant questionnaire data and BP were collected 4 times, at the start and end of each filtration period. PM concentrations were measured in a subset of residences. Linear mixed models were used to compare the mean change in BP between the HEPA and sham filtration periods. Models were adjusted for time invariant and time-varying covariates.
Results: A total of 154 participants were analyzed. The mean age was 41.1 years, 59.7% were women, 68.2% were non-Hispanic White, and a majority were of higher socioeconomic status. The mean baseline brachial systolic blood pressure (SBP)/diastolic BP was 118.8/76.5 mm Hg. HEPA filtration significantly reduced PM in comparison to both indoor sham and outdoor levels. Participants' SBP at the start of the intervention period moderated the efficacy of the intervention (P = 0.03). Participants who had elevated brachial SBP (≥120 mm Hg) had a significant 2.8-mm Hg mean reduction in SBP after HEPA filtration (P = 0.03) and a 0.2-mm Hg mean increase in SBP after sham filtration (P = 0.85). The net result was a significant 3.0-mm Hg mean difference in favor of HEPA filtration (P = 0.04). There was no significant benefit on diastolic BP or for participants with normal SBP (<120 mm Hg).
Conclusions: The use of in-home HEPA air purifiers resulted in clinically important reductions in SBP for people with elevated SBP in environments with relatively low PM2.5 concentrations.
Keywords: HEPA air filtration; air purifiers; blood pressure; highway traffic; particulate matter pollution; randomized crossover trial.
Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Funding Support and Author Disclosures This study was supported by the National Institute of Environmental Health Sciences Grant ID: R01 ES030289 and the School of Medicine at the University of Connecticut. The air purifiers were custom adapted by the manufacturer, Austin Air, and sold at a discount based on bulk purchase. The manufacturer was not involved in any way in the design, conduct or analysis. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Similar articles
-
Altered dietary salt intake for preventing diabetic kidney disease and its progression.Cochrane Database Syst Rev. 2023 Jan 16;1(1):CD006763. doi: 10.1002/14651858.CD006763.pub3. Cochrane Database Syst Rev. 2023. PMID: 36645291 Free PMC article.
-
CPAP vs Mandibular Advancement Devices and Blood Pressure in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta-analysis.JAMA. 2015 Dec 1;314(21):2280-93. doi: 10.1001/jama.2015.16303. JAMA. 2015. PMID: 26624827
-
Long-Term Safety and Efficacy of Renal Denervation: 24-Month Results From the SPYRAL HTN-ON MED Trial.Circ Cardiovasc Interv. 2025 Jul;18(7):e015194. doi: 10.1161/CIRCINTERVENTIONS.125.015194. Epub 2025 May 20. Circ Cardiovasc Interv. 2025. PMID: 40391448 Free PMC article. Clinical Trial.
-
Utility of a Systolic Blood Pressure Polygenic Risk Score With Chlorthalidone Response.JAMA Cardiol. 2024 Dec 1;9(12):1134-1141. doi: 10.1001/jamacardio.2024.3649. JAMA Cardiol. 2024. PMID: 39441603 Clinical Trial.
-
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.Lancet Diabetes Endocrinol. 2022 Sep;10(9):645-654. doi: 10.1016/S2213-8587(22)00172-3. Epub 2022 Jul 22. Lancet Diabetes Endocrinol. 2022. PMID: 35878651 Free PMC article.
LinkOut - more resources
Full Text Sources